Photo: Mikael Sjoberg/Bloomberg via Getty Images. Pharmaceuticals giant AstraZeneca has closed on a deal with US-based biotech AbSci Corporation to develop an antibody therapy for an undisclosed cancer using Absci’s AI technology. The deal, signed yesterday (3 November), is worth up to $247m, according to the Financial Times.
How will AstraZeneca collaborate with absci?
This collaboration combines Absci’s Integrated Drug Creation™ platform with AstraZeneca’s expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target.
What is AstraZeneca's $247m deal with absci?
The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer. AstraZeneca has signed a deal with US biopharma Absci. Photo: Mikael Sjoberg/Bloomberg via Getty Images.
